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Abstract
Background: Blood-born miRNA signatures have recently been reported for various tumor diseases. Here, we
compared the miRNA signature in Wilms tumor patients prior and after preoperative chemotherapy according to
SIOP protocol 2001.
Results: We did not ﬁnd a signiﬁcant diﬀerence between miRNA signature of both groups. However both, Wilms
tumor patients prior and after chemotherapy showed a miRNA signature diﬀerent from healthy controls. The
signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after
chemotherapy an accuracy of 97.0%, each as compared to healthy controls.
Conclusion: Our results provide evidence for a blood-born Wilms tumor miRNA signature largely independent of
four weeks preoperative chemotherapy treatment.
Background
Wilms tumor is a common childhood tumor and aﬀects
very young children [1]. Most of cases are detected at the
median age of 36 months. In Europe, children older than
six months are treated with preoperative chemotherapy
according to the SIOP protocol (Societe´ Internationale
d’Oncologie Pe´diatrique) resulting in a smaller tumor vol-
ume when children undergo surgery. The primary aims
of the SIOP study are risk-stratiﬁed therapies, dimished
toxicity and an improved patient outcome. Since chil-
dren in early stages of Wilms tumor development do
not show characteristic symptoms, and low grade tumors
have a better prognosis than high grade tumors [2], an
early detection marker is useful to increase the overall
survival rates. Most recently, we provided strong evi-
dence that blood-bornmicroRNA (miRNA) signatures are
highly indicative for various human diseases [3]. MiRNAs
are small non-coding RNAs between 17 and 24 nt. They
are involved in physiological and pathological processes
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through the regulation of gene expression and may indi-
cate tumor development at very early stages [4,5]. Speciﬁc
miRNA signatures have already been described for clear
cell renal cell carcinoma (ccRCC) [6]. They allow to diﬀer-
entiate metastatic and non-metastatic ccRCC and indicate
progression-free survival and overall survival. MiRNA
proﬁles of diﬀerent human kidney cancer subtypes have
been established by Petillo et al. [7]. They were able to dis-
criminate chromophobe RCC from oncocytomas, ccRCC
from papillary RCC and prognostic subgroups of ccRCC.
While these renal miRNA patterns have been established
on tumor tissues, in our study we analyzed the miRNA
expression pattern in blood cells of Wilms tumor patients.
Speciﬁcally we compared untreated children with Wilms
tumor and children treated according to SIOP protocol.
We asked if chemotherapy aﬀects the miRNA expression
patterns. In addition, we asked if these expression patterns




In total, we collected more than hundred blood samples
from Wilms tumor patients. To arrvive at homogenous
© 2012 Schmitt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Schmitt et al. BMC Genomics 2012, 13:379 Page 2 of 8
http://www.biomedcentral.com/1471-2164/13/379
patient groups, we excluded samples taken from patients
after primary surgery, from patients with relapses,
from patients after post-chemotherapy surgery and from
patients with a non-Wilms tumor histology as deter-
mined by biopsy. We obtained 43 Wilms tumor sam-
ples for analysis, including 23 samples taken from Wilms
tumor patients prior to chemotherapy and 20 samples
from patients after chemotherapy. Out of these were 26
matched samples, i.e. 13 samples prior to chemotherapy
and 13 samples after chemotherapy of the same patients.
The mean age of the treated patients was 3.3 years +/-
2.2, the mean age of the untreated patients was 4.9 years
+/- 3.9. The collection contained 41 samples of unilat-
eral and 2 samples of bilateral tumors. Detailed patient
information is available in Additional ﬁle 1: Table S1.
We also collected blood samples with the consent of 19
healthy controls. The mean age of healthy controls was
37.8 years +/- 14.2. In each case, 2.5 ml peripheral blood
was collected in PAXgene Blood RNA tubes (BD, Franklin
Lakes, NJ, USA) and stored at -20◦C. Blood samples
were obtained with parents’ informed consent from the
Department of Pediatric Hematology and Oncology of the
Saarland University and from the multicenter study SIOP
2001/GPOH. The study was approved by the local ethics
committee (No.136/01). Detailed information is available
in Additional ﬁle 1: Table S2.
RNA isolation andmicroarray screening
To isolate the RNA including the miRNA from whole
blood samples, we used themiRNeasy Kit (Qiagen GmbH,
Hilden) as previously described [8]. We analyzed the
total RNA by using the Geniom RT Analyzer (febit
biomed GmbH, Heidelberg, Germany) employing the
MPEA-assay for miRNA-analysis. This assay allows for
detection of microRNAs based on a combination of strin-
gent hybridization and enzymatic primer extension on a
microﬂuidic microarray starting from total RNA mate-
rial, without the need for enrichment, ampliﬁcation or
labeling of the native RNA samples [9]. The microﬂu-
idic biochip (Geniom Biochip Homo sapiens v12, febit
biomed GmbH, Heidelberg, Germany) contained 7 repli-
cates of 848 miRNAs [10,11] as annotated in the Sanger
miRBase version 12.0 (www.mirbase.org). The expres-
sion proﬁles are deposited in the GEO (Gene Expres-
sion Omnibus) database under the accession number
GSE38419.
Quantitative Real-Time PCR
Relative quantiﬁcation Real-Time PCR (qRT-PCR) was
performed to conﬁrm the array results on an a
StepOnePlus™ Real-Time PCR System (Applied Biosys-
tems, Foster City, USA). The miScript PCR System
(Qiagen, Valencia, CA, USA) was used and all pro-
cedures were carried out according to manufacturer’s
recommendations. Brieﬂy, 250 ng of total RNA containing
miRNAs was mixed with 4 μl of miScript RT Buﬀer and 1
μl miScript Reverse Transcriptase mix, RNase-free water
in a total volume of 20 μl (Qiagen, Valencia, CA, USA).
Samples were further incubated at 37◦C for 60 min for the
ﬁrst strand cDNA synthesis. Thereafter, the reaction was
inactivated by heating at 95◦C for 15 min and the result-
ing cDNA was stored at -20◦C until analysis. The cDNA
converted from total RNA containing miRNAs served as
the template for Real-time PCR analysis using the miS-
cript SYBR Green PCR Kit along with the 10x miScript
Primer Assays for hsa-miR-520d-3p, hsa-miR-197, hsa-
miR-224, hsa-miR-20a, hsa-miR-126, and hsa-miR-144*
(Qiagen, Valencia, CA, USA). Each PCR reaction con-
tained: 2.5 μl cDNA, 12.5 μl 2x QuantiTect SYBR Green
PCR Master Mix, 2.5 μl 10x miScript Universal Primer,
2.5 μl 10x miScript Primer Assay and RNase-free water
to a total volume of 25 μl, and placed into the individual
wells of a 96-well plate. Reactions were run with the fol-
lowing thermal cycling parameters: initial activation step
95◦C for 15 min followed by 40 cycles at 94◦C for 15 sec
(denaturation), 55◦C for 30 sec (annealing) and 70◦C for
30 sec (extension). Then a ﬁnal dissociation curve (melting
curve) was made, and PCR plates were kept at 4◦C until
they were taken out from the PCR machine. The RNU6B
snRNAs primer assay (Qiagen, Valencia, CA, USA) was
chosen as an endogenous reference for normalization
studies.
Statistical analysis
The background corrected and log transformed microar-
rays were quantile normalized using the freely available
R software [12]. Diﬀerentially expressed miRNAs were
identiﬁed by employing an unpaired two-tailed t-test.
The resulting p-values were adjusted for multiple test-
ing by applying the Benjamini-Hochberg procedure (false
discovery rate (FDR) adjustment) [13]. In addition, we
computed AUC (Area Under the Curve) values for each
miRNA. AUC values measure how well the expression
values of a single miRNA can separate two groups, e.g.
patients versus controls. An AUC value of 0.5 indicates
equal distribution of the two groups to compare; this
means that a miRNA cannot be used to separate the
groups. A miRNA reaching an AUC value of 1 (0) has
expression values that are throughout lower (higher) in
the diseased group than in the control group correspond-
ing to the most diagnostic information of a biomarker.
Besides this single biomarker analysis, we classiﬁed
the samples using the normalized and log transformed
miRNA expression proﬁle with machine learning proce-
dures for calculating Support Vector Machines (SVM)
implemented in the R e1071 package. We performed the
classiﬁcation with a linear SVM employing 100 repetitions
of standard 10-fold cross validation and calculated mean
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sensitivity, speciﬁcity, and accuracy. Clustering has been
carried out using complete linkage hierarchical clustering.
The Euclidian distance measure was employed to com-
pute the dissimilarity of miRNA rows and sample columns
independently of each other. We used the heatmap.2
function of the gplots R package to compute and plot
the results of the clustering. For validating the microar-
ray results, we applied quantitative real-time PCR on six
selected miRNAs and computed the fold change by using
the 2−Ct method [14].
Results
In total, we collected 43 Wilms tumor samples for analy-
sis. To generate miRNA proﬁles, we screened 848 mature
miRNA transcripts. After applying background correc-
tion, log transformation, and normalization procedures,
we tested if the miRNA proﬁle changes after chemother-
apy. To this end, we applied the paired two-tailed t-test for
the matched samples of 13 Wilms tumor patients before
and after chemotherapy. We considered only miRNAs
with more than a two-fold expression diﬀerence between
the two groups. Using the remanining 214 miRNAs, our
analysis did not indicate a signiﬁcant diﬀerence in miRNA
proﬁles of Wilms tumor patients prior to chemotherapy
and Wilms tumor patients after chemotherapy. Speciﬁ-
cally, we did not ﬁnd signiﬁcantly deregulated miRNAs
using a signiﬁcance threshold of 0.05 after FDR adjust-
ment. In addition, we repeated the comparison of Wilms
patients before and after therapy using all 43 samples and
applying unpaired two-tailed t-test, which conﬁrmed the
results of the matched samples (no signiﬁcant miRNA
using a signiﬁcance threshold of 0.05 and FDR adjust-
ment). The lack of a diﬀerence between post- and pre-
treatment samples prompted us to ask whether Wilms
tumors are characterized by a blood-born miRNA sig-
nature. To this end, we compared Wilms tumor patients
prior chemotherapy with healthy controls. In detail, we
compared 23 samples from Wilms tumor patients prior
to chemotherapy with 19 healthy controls. After FDR
p-value adjustment at a signiﬁcance level of 0.05 using
unpaired two-tailed t-test, we found 176 signiﬁcantly
deregulated miRNAs including 79 down-regulated and
97 up-regulated miRNAs in blood cells of Wilms tumor
patients. The most signiﬁcantly up-regulated miRNAs
were hsa-miR-766, hsa-miR-1246, hsa-miR-197, and hsa-
miR-224 with an increased median expression of 3.0-
9.6 fold. The most signiﬁcantly down-regulated miRNAs
hsa-miR20a, hsa-miR-20b, hsa-miR-144* and hsa-miR-
144 displayed median expression factors of 2.9-6.9 in
Wilms tumor patients compared to control samples. The
176 deregulated miRNAs including their fold change, p-
values, and AUC values are available in Additional ﬁle 2:
Table S1. An overview of the 20 most signiﬁcantly dereg-
ulated miRNAs can be found in Table 1.
Using hierarchical clustering with the Euclidian dis-
tance measure, we analyzed how the 42 Wilms tumor
and control samples relate to each other. For this task
we used the 100 most variable miRNAs out of the 848
miRNAs. Figure 1 shows the resulting heatmap of the
hierarchical clustering. The control samples clearly clus-
ter diﬀerent from theWilms tumor samples. To determine
if the expression pattern of the 848 miRNAs are able
to separate Wilms tumor patients prior to chemother-
apy from controls, we used a Support Vector Machine
(SVM) with linear kernel. Brieﬂy, we applied 100 rep-
etitions of 10-fold cross-validations and computed the
mean accuracy, sensitivity, speciﬁcity, and the corre-
sponding 95% conﬁdence intervals. Using this cluster-
ing, we were not able to separate Wilms tumor patients
prior to chemotherapy and patients after chemotherapy,
conﬁrming the fold-expression results as shown above.
But we were able to reach high values for the separa-
tion between blood samples taken from Wilms tumor
patients prior to chemotherapy and samples taken from
healthy controls with very low variances. In detail we
found 97.5% accuracy (97.4 - 97.7%), 99.8% sensitivity
(99.6 - 99.9%), and 94.7% speciﬁcity (94.6- 94.8%) for this
separation.
Likewise we found comparable results for the separa-
tion between samples taken from Wilms tumor patients
after chemotherapy and samples taken from controls. In
detail we calculated an accuracy of 97.0% (96.7 - 97.3%)
a sensitivity of 99.1% (98.5 - 99.7%) and a speciﬁcity of
94.8% (94.7 - 95.0%). These results support the abovemen-
tioned results that showed no signiﬁcant diﬀerence of the
blood-born miRNA signature between patients prior and
after chemotherapy. Finally, we determined those miR-
NAs that are diﬀerently regulated in both comparisions
between controls and samples taken prior to preoper-
ative chemotherapy and between controls and samples
taken after preoperative chemotherapy. We found a total
of 106 miRNAs that were diﬀerentially regulated in both
comparisons (adjusted t-test, signiﬁcance level 0.05) (see
Figure 2). Interestingly, the overlap consists of 43 miRNAs
that are down-regulated and of 63 miRNAs that are up-
regulated in both comparisons. These miRNAs are likely
to contribute most to the treatment independent Wilms
tumor signature.
To validate our microarry results, we selected six miR-
NAs for performing quantitative reverse transcription
PCR (qRT-PCR). In total, we chose three miRNAs that
were up-regulated (miR-520d-3p, miR-197, miR-224), and
three that were down-regulated (miR-20a, miR-126, miR-
144*) in the microarray experiment comparing Wilms
tumor samples against normal controls. We performed
the qRT-PCR in duplicates with 10 samples per group.
The qRT-PCR results for the tested miRNAs were largely
concordant with the microarray data (Figure 3), except
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Table 1 The 20most signiﬁcant miRNAs inWilms tumor patients before therapy
Log Log Log
MiRNA median median diﬀerence Fold Ttest Ttest adj AUC
Wilms Control
hsa-miR-20a 10.124 12.929 -2.805 -6.988 7.01E-012 5.94E-009 0.977
hsa-miR-20b 10.057 12.410 -2.353 -5.108 2.49E-011 1.05E-008 0.984
hsa-miR-766 10.079 8.494 1.585 3.000 2.63E-009 3.29E-007 0.033
hsa-miR-144* 7.994 9.524 -1.531 -2.889 2.40E-009 3.29E-007 0.953
hsa-miR-144 8.967 11.506 -2.540 -5.815 2.71E-009 3.29E-007 0.954
hsa-miR-106a 11.506 13.639 -2.132 -4.385 2.14E-009 3.29E-007 0.950
hsa-miR-1246 6.007 2.737 3.270 9.649 1.36E-009 3.29E-007 0.059
hsa-miR-197 11.205 8.888 2.317 4.984 4.33E-009 4.59E-007 0.055
hsa-miR-224 6.403 3.745 2.658 6.310 5.20E-009 4.90E-007 0.043
hsa-miR-18a 9.168 11.205 -2.037 -4.104 6.75E-009 5.72E-007 0.962
hsa-miR-93 10.830 12.766 -1.936 -3.825 8.50E-009 6.55E-007 0.935
hsa-miR-17 11.839 13.273 -1.434 -2.702 1.20E-008 8.48E-007 0.962
hsa-miR-18b 7.044 8.901 -1.856 -3.621 2.02E-008 1.32E-006 0.982
hsa-miR-126 8.320 11.425 -3.104 -8.601 3.38E-008 2.05E-006 0.944
hsa-miR-520d-3p 4.497 2.134 2.363 5.145 4.13E-008 2.33E-006 0.061
hsa-miR-1305 4.877 6.898 -2.021 -4.058 5.14E-008 2.60E-006 0.966
hsa-miR-373 4.819 1.976 2.843 7.173 5.22E-008 2.60E-006 0.064
hsa-miR-106b 13.004 14.104 -1.100 -2.143 6.24E-008 2.94E-006 0.938
hsa-miR-1204 5.360 3.048 2.312 4.967 1.21E-007 5.42E-006 0.078
hsa-miR-374a 6.473 8.483 -2.010 -4.029 1.39E-007 5.91E-006 0.934
The 20 most signiﬁcant miRNAs when comparing Wilms patients before therapy to healthy controls. Down-regulated fold-change is indicated by negative values,
up-regulated fold-change is indicated by positive values.
for miR-520d-3p, which is down-regulated in qRT-PCR
instead of its up-regulation in the microarry experiment.
Discussion
As shown in several studies, miRNA expression signatures
allow diﬀerentiation between human cancers [15,16].
There is also evidence that miRNA signatures correlate
with metastasis, progression-free survival and overall sur-
vival [6]. As for human kidney cancer, speciﬁc signatures
have been reported for clear cell renal cell carcinoma
(ccRCC), papillary RCC and prognostic subgroups of
ccRCC [7]. While the majority of studies focused on miR-
NAs in tissues, there is increasing evidence that miRNAs
isolated from body ﬂuids like serum, plasma or blood
cells, can serve as an informative marker for diﬀerent can-
cer types like ovarian cancer, prostate cancer, lung cancer,
colorectal cancer as reviewed by Cortez et al. [17]. Most
recently we reported speciﬁcmiRNA signatures of periph-
eral blood cells in a variety of cancer and non-cancer
diseases. In detail, we detected consistently deregulated
proﬁles for lung cancer, prostate cancer, melanoma, ovar-
ian cancer, gastric tumors, pancreatic tumors, multiple
sclerosis, chronic obstructive pulmonary disease (COPD),
sarcoidosis, periodontitis, pancreatitis and acute myocar-
dial infarction [3]. Based on our data and the data of others
[18], the overall pattern ofmiRNAs from blood cells seems
to be rather robust. In addition, blood cells allow isola-
tion of rather large amounts of miRNAs that in turn are
suﬃcient for next generation sequencing of miRNAs [19].
In the present study, we were able to diﬀerentiate
between healthy controls and samples that were taken
from Wilms tumor patients prior to chemotherapy with
an accuracy of 97.5%. Several of the miRNAs that were
signiﬁcantly deregulated in this comparison have been
associated with non-tumor diseases including miR-144*
that is overexpressed in patients with active tuberculosis
(TB) [20], miR-1246 that seems to play a role in the down-
regulation of the Down Syndrome-associated DYRK1A
[21] and miR-216a that was deregulated in mouse kidney
with diabetic nephropathy [22]. In addition somemiRNAs
that we found diﬀerentially expressed in our analysis, have
previously been associated with cancer including miR-20b
that is decreased in plasma vesicles of non-small cell lung
cancer patients [23], miR-197 that is under-expressed in
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Figure 1 Clustering of the 100 most variable miRNAs. Clustering of the 100 most variable miRNAs for the classiﬁcation between Wilms tumor
patients prior to chemotherapy and healthy controls. Complete linkage hierarchical clustering has been performed with the Euclidian distance
measure. Wilms patients and healthy controls cluster separately. The colors in the heatmap represent the normalized expression values with lower
expression values being colored in shades of green and higher expression values in shades of red.
oral tumor tissue [24], and miR-144 that has been gen-
erally described as tumor speciﬁc miRNA by Wang et al.
[25].
Notably, some of the miRNAs that we found diﬀer-
entially expressed between Wilms tumor patients and
controls have previously been related to kidney cancers.
Speciﬁcally miR-20a that is a member of the miR-17-92
cluster, has been correlated to alveolar rhabdomyosar-
coma as reported by the Children’s Oncology Group
(COG) [26] and is implicated in pathways linked toWilms
tumor [27]. There is evidence that miR-106b, which is
highly expressed during nephrogenesis in nephron pro-
genitors [28], is a predictive marker of early metastasis
after nephrectomy in RCC patients [29]. The miR-17-92
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Figure 2 Venn diagram of signiﬁcantly deregulated miRNAs prior and after chemotherapy. Venn diagram of miRNAs signiﬁcantly
deregulated in Wilms tumor patients prior and after chemotherapy compared to normal controls. There is an overlap of 106 miRNAs that are
signiﬁcantly deregulated in both groups. The overlap consists of 43 miRNAs that are in both comparisons down-regulated, and of 63 miRNAs that
are in both comparisons upregulated.
cluster, also known as oncomir-1, is a miRNA polycistron
that contains some of themost potent oncogenicmiRNAs.
The oncogenic eﬀect of oncomir-1 was not only found
in kidney cancer [30,31] but also in a broad spectrum of
other malignancies including e.g. colon [32], bladder [33]
or gastrointestinal cancer [34]. miR-126 a known angio-
genic miRNA allowed diﬀerentiation between papillary
RCC and ccRCC [35]. miR-126 has also been proposed
to separate conventional from papillary renal tumors [36].
Increased levels of miR-224 have been found in ccRCCs
[37].
Another interesting result of this study is that we did
not ﬁnd signiﬁcantly deregulatedmiRNAs betweenWilms
tumor patients prior and after chemotherapy. Presently,
we conclude that the tumor type seems to mainly deter-
mine the miRNA signature that is found in blood cells of
the patients. Since the analyzed blood cells comprise B
cells, T cells and NK cells, it is legitimate to speculate that
the identiﬁed miRNA signatures reﬂect a tumor type spe-
ciﬁc immune response. This hypothesis awaits of course
future experimental conﬁrmation.
We are well aware that healthy adults are not the opti-
mal control for diseased children. The improvement for
blood withdrawal of healthy children is, however, a major
hurdle for the time being, we do not have such an approval
by the local ethic committee. However, we compared our
Wilms tumor samples to samples taken from children
with other tumor diseases. We have preliminary data that
seems to indicate that these both groups can be separated
by miRNA signatures (data not shown). These results
provide further evidence for a Wilms speciﬁc miRNA
signature.
Figure 3 Comparison of the fold changes of microarray experiment and qRT-PCR. Comparison of the fold changes of six miRNAs found
deregulated in Wilms patients in the microarray experiment and the corresponding qRT-PCR results.
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Conclusions
The present study provides ﬁrst evidence for a miRNA
signature found in blood cells of Wilms tumor patients.
This signature shows an accuracy of 97.5% as compared to
healthy controls and appears independent of chemother-
apy. Since Wilms tumor patients undergo chemotherapy
without prior histological analysis, an accurate blood-
born biomarker like the identiﬁed miRNA signature may
be helpful to avoid misdiagnosis and subsequent wrong
treatment.
Additional ﬁles
Additional ﬁle 1: Table S1. Patient data of Wilms tumor samples. Detailed
information about the diagnosis of Wilms tumor patients. Table S2. Data
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Additional ﬁle 2: Table S1. Overview of signiﬁcantly deregulated miRNAs
in Wilms before therapy compared to normal controls. The 176
deregulated miRNAs including their fold change, p-values, and AUC values
of the comparison Wims before therapy versus normal controls.
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